Medical Properties Trust: An Odd Dividend Hike Against Heavy Debt Burden
Summarize this article with:
Pacifica Yield13.45K FollowersFollow5ShareSavePlay(6min)CommentsSummaryMedical Properties Trust raised its dividend by 12.5% despite ongoing balance sheet pressures and asset sales.MPW trades at a 9.5x NFFO multiple faces $1.15 billion in maturing debt in 2026 and $1.6 billion maturing in 2027.The REIT's cash from operations remains weak, and asset sales are likely needed to address near-term refinancing risks.I rate MPW as a hold, viewing the dividend hike and buyback as misaligned with its debt and operational headwinds. Jason Finn/iStock via Getty Images Medical Properties Trust (MPW) recently hiked its dividend by double digits, even as a substantial debt burden and asset sales look set to pressure its balance sheet in the medium term. The internally managedThis article was written byPacifica Yield13.45K FollowersFollowThe equity market is a powerful mechanism as daily fluctuations in price get aggregated to incredible wealth creation or destruction over the long term. Pacifica Yield aims to pursue long-term wealth creation with a focus on undervalued yet high-growth companies, high-dividend tickers, REITs, and green energy firms.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.